At the heart of our involvement is the presentation of our innovative research through the poster titled, “Single cell profiling of biostabilized natural human skin identifies mast cells as an important target of injected mRNA-1273 COVID-19 vaccine”. This research highlights the cutting-edge methodologies employed by Genoskin to explore the human skin’s immune response to vaccines, particularly the Moderna mRNA-1273 COVID-19 vaccine, within its natural tissue context.

Our research embodies an innovative approach in vaccination research, focusing on the need for technological platforms that can generate human data prior to the initiation of clinical trials. We utilize bioengineering to repurpose surgical resections, offering a detailed analysis of vaccine responses at both organ and single-cell levels. Our key findings include the identification of mast cells as a primary target for vaccine mRNA, alongside DC/macrophages, regardless of the administration route. This underscores the natural affinity of LNP-loaded mRNA vaccines to these cell types, providing invaluable insights with direct implications for vaccine development strategies.

Mast cells, central to our research, play a dual role in both immunity and disease, especially in allergic reactions. Their involvement extends to various physiological and pathological conditions, emphasizing their significance within the vaccine response framework. Our presentation at EMBRN 2024 highlights the potential of targeting mast cells to enhance the efficacy and safety of vaccines, providing invaluable insights that could revolutionize vaccine development. This approach not only sheds light on the complex interactions within the human skin ecosystem in response to vaccinations but also sets the stage for more precise and effective immunization strategies.

In line with our research, we were proud to present our Human Primary Mast Cells service at the EMBRN meeting. This service reinforces our commitment to advancing mast cell research, offering a valuable resource for scientists and developers working on novel therapies and vaccines. Discover how our services can help you evaluate the in vitro mast cell response to your compound or formula.

We had the great opportunity to present our findings and to engage with the international community at the EMBRN meeting. The conference was a catalyst for new ideas and discussions, showcasing groundbreaking research through keynote speeches, plenary sessions, and poster presentations.

Learn more about our mast cell research and how our services can support your projects by visiting Genoskin’s Mast Cells service page.

For more details on the EMBRN meeting, visit the EMBRN 2024 website.